- Home
- VBIX vs AYTU Comparison
VBIX vs AYTU Comparison
Compare VBIX & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VBIX | AYTU |
|---|---|---|
| Founded | N/A | N/A |
| Country | Israel | United States |
| Employees | 21 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 25.7M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | VBIX | AYTU |
|---|---|---|
| Price | $1.90 | $2.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 33.0K | ★ 42.5K |
| Earning Date | 03-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,632,080.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $0.96 | $0.98 |
| 52 Week High | $6.31 | $3.07 |
Technical Indicators
Market Signals| Indicator | VBIX | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 50.63 | 48.08 |
| Support Level | $1.51 | $2.46 |
| Resistance Level | $3.70 | $2.66 |
| Average True Range (ATR) | 0.22 | 0.11 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 53.97 | 23.33 |
Price Performance
Historical ComparisonAbout VBIX Viewbix Inc.
ViewBix Inc operates in the field of digital advertising. The company operates in single segment, the search segment that develops various technological software solutions, which perform automation, optimization, and monetization of internet campaigns, to obtain and route internet user traffic to its customers.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.